Submission Tilte
Anticoagulation Therapy in Special Populations with Atrial Fibrillation: Challenges and Advances
Submission Abstract:
Atrial fibrillation (AF) remains the most common sustained cardiac arrhythmia worldwide, and anticoagulation therapy is central to preventing AF-related thromboembolic complications. However, clinical management becomes increasingly complex in special populations characterized by comorbidities, frailty, or altered pharmacokinetics, such as the elderly, patients with renal or hepatic impairment, those with prior bleeding, cancer, or pregnancy, and individuals with unique genetic or ethnic profiles. This Thematic Issue, “Anticoagulation Therapy in Special Populations with Atrial Fibrillation: Challenges and Advances,” aims to comprehensively explore the latest clinical evidence, risk–benefit considerations, and emerging therapeutic strategies in these high-risk groups. It emphasizes precision medicine, real-world data integration, and multidisciplinary, patient-centered approaches to optimize efficacy and safety. By bridging current knowledge gaps and highlighting future directions, this issue seeks to guide evidence-based practice and foster innovation in anticoagulation therapy for diverse AF populations.